I don’t think there has been any history of Nade
Post# of 154969
(Total Views: 453)
Posted On: 03/06/2021 11:29:27 AM
I don’t think there has been any history of Nader having any strategy behind when and what a pr is released and what it says. He has always just put out the info as it is available and stuck to the minimum, with exception to his quoted comments that are distinguished as his opinion. It is very clear the prs are following the lawyers review. Cytodyn is in no way trying to explain the pr with too much depth. The only time Nader snuck in a surprise was the Vyera deal near the end of a ho-hum CC.
It could be the CC on Monday will have block buster news, I don’t think the pr last night was part of a set up to trick shorts, I think it was what cytodyn had available to pr. I’m sure Nader is avoiding any lawsuit possible and withholding bad news that they could have included in the pr is certain to earn a lawsuit. The severe data must be heading our way, how could they think that we are so dumb to not ask?
I also have to repeat this, there just can’t be no benefit from leronlimab in severe condition patients. It shows effectiveness for moderate, it clearly shows effectiveness in critical, it can’t just skip over severe. It could be the FDA is laser focused on critical and that is what the discussions are all about, the FDA clearly did not care about M/M.
I hope there is a logical reason for the pr last night and it is not just another example of Cytodyn thinking the pr is perfect and the rest of us just don’t understand. Maybe there was a lot of editing by the lawyers, maybe we get some idea as to why the DSMC wanted 42 day data?
It could be the CC on Monday will have block buster news, I don’t think the pr last night was part of a set up to trick shorts, I think it was what cytodyn had available to pr. I’m sure Nader is avoiding any lawsuit possible and withholding bad news that they could have included in the pr is certain to earn a lawsuit. The severe data must be heading our way, how could they think that we are so dumb to not ask?
I also have to repeat this, there just can’t be no benefit from leronlimab in severe condition patients. It shows effectiveness for moderate, it clearly shows effectiveness in critical, it can’t just skip over severe. It could be the FDA is laser focused on critical and that is what the discussions are all about, the FDA clearly did not care about M/M.
I hope there is a logical reason for the pr last night and it is not just another example of Cytodyn thinking the pr is perfect and the rest of us just don’t understand. Maybe there was a lot of editing by the lawyers, maybe we get some idea as to why the DSMC wanted 42 day data?
(3)
(0)